Genentech looks to market first eye implant for AMD
Genentech has developed an implant to deliver ranibizumab directly into the eye of patients.
Archives for August 3, 2018
Bluebird’s ‘one-time gene therapy’ receives EMA accelerated assessment
Bluebird bio’s LentiGlobin gene therapy has received an accelerated assessment from the EMA for the treatment of transfusion-dependent β-thalassemia.
Merck KGaA and Pfizer sign combo immunotherapy treatment deal
Leap Therapeutics partners with Merck KGaA and Pfizer for Phase I/II clinical trial for immunotherapy regime for solid tumors.
Daiichi Sankyo and Glycotope reach agreement for “first-in-class” ADC
Daiichi Sankyo and Glycotope have signed a licensing agreement to develop an antibody-drug conjugate that enables tumor-specific binding to TA-MUC1.